Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Behavioral: Monitoring by an HIV-trained medical doctor
Behavioral: Monitoring by an HIV-trained primary care nurse
Drug: Efavirenz
Drug: Lamivudine
Drug: Lopinavir/Ritonavir
Drug: Nevirapine
Drug: Stavudine

First Posted Date: 2005-11-21

Last Posted Date: 2011-06-21

Lead Sponsor: CIPRA SA

Target Recruit Count: 812

Registration Number: NCT00255840

When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Abacavir
Drug: Efavirenz
Drug: Lamivudine
Drug: Lopinavir/Ritonavir
Drug: Nelfinavir
Drug: Nevirapine
Drug: Zidovudine

First Posted Date: 2005-10-06

Last Posted Date: 2013-12-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00234091

Locations: 🇰🇭
National Pediatric Hosp., Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇰🇭
Social Health Clinic, Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇹🇭
Prapokklao Hosp. CIPRA CRS, Chantaburi, Thailand

and more 6 locations

Combination of Efavirenz and Truvada - COMET Study

Phase 4

Completed

Conditions: HIV Infections

First Posted Date: 2005-09-23

Last Posted Date: 2008-04-10

Lead Sponsor: Gilead Sciences

Target Recruit Count: 400

Registration Number: NCT00224458

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Conditions: HIV Infection

First Posted Date: 2005-09-13

Last Posted Date: 2014-01-09

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00162227

Locations: 🇺🇸
Children'S Hospital, Boston, Massachusetts, United States
🇺🇸
State University Of New York At Stony Brook, Stony Brook, New York, United States
🇺🇸
Metro Health Medical Center, Cleveland, Ohio, United States

and more 21 locations